Lasa Supergenerics Limited LASA NSEPHARMA
Company Overview
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.20.
Recent Developments
- Mar 2026 Revenue of ₹25.14 Cr (-82.4% YoY); net profit ₹-34.09 Cr.
- Trailing 12 Months Year-on-year growth — revenue -93.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -42.1%, profit CAGR 3.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -42.11% |
| 1 Year: | -93.40% |
Compounded Profit Growth
| 5 Years: | 3.91% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -33.95% |
| 6 Months: | -10.62% |
| 3 Months: | -12.26% |
| 1 Month: | -14.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -42.1% CAGR over 5 years.
- Trading 51.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LASA Lasa Supergenerics Limited NSEPHARMA | 6.73 | -2.05 | ₹33.72 Cr | 0.00% | -69.14% | -68.70% | -42.11% | 3.91% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 39.14 Cr | 20.01 Cr | 3.06 Cr | 2.20 Cr | -13.15 L |
| Cost of Revenue | - | 28.33 Cr | 15.69 Cr | 5.53 Cr | 2.26 Cr | 36.35 L |
| Gross Profit | - | 10.81 Cr | 4.32 Cr | -2.47 Cr | -6.01 L | -49.50 L |
| Operating Expenses | - | 11.30 Cr | 6.39 Cr | 3.10 Cr | 2.26 Cr | 2.93 Cr |
| Operating Income | - | -48.62 L | -2.07 Cr | -5.57 Cr | -2.32 Cr | -3.43 Cr |
| EBITDA | - | -18.11 Cr | -20.94 Cr | -3.99 Cr | -74.77 L | -2.54 Cr |
| Interest Expense | - | 10.77 L | 2.60 L | 11.95 L | - | 12.86 L |
| Pretax Income | - | -22.12 Cr | -22.54 Cr | -5.68 Cr | -2.41 Cr | -3.98 Cr |
| Tax Provision | - | -7.83 Cr | -1.42 Cr | 57.13 L | 14.32 L | 18.76 L |
| Net Income | - | -14.29 Cr | -21.12 Cr | -6.25 Cr | -2.55 Cr | -4.16 Cr |
| Diluted EPS | - | -2.85 | -4.22 | 1.25 | -0.51 | -0.83 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 129.57 Cr | 104.33 Cr | 142.45 Cr | 25.14 Cr |
| Cost of Revenue | - | 106.47 Cr | 75.22 Cr | 106.19 Cr | 23.84 Cr |
| Gross Profit | - | 23.10 Cr | 29.12 Cr | 36.26 Cr | 1.30 Cr |
| Operating Expenses | - | 41.19 Cr | 37.62 Cr | 42.29 Cr | 14.68 Cr |
| Operating Income | - | -18.10 Cr | -8.51 Cr | -6.03 Cr | -13.38 Cr |
| EBITDA | - | -24.69 Cr | -6.51 Cr | -4.39 Cr | -28.20 Cr |
| Interest Expense | - | 4.15 Cr | 1.93 Cr | 2.69 Cr | 38.62 L |
| Pretax Income | - | -42.27 Cr | -19.11 Cr | -19.38 Cr | -34.61 Cr |
| Tax Provision | - | -3.64 Cr | 2.62 Cr | -4.63 Cr | -51.74 L |
| Net Income | - | -38.62 Cr | -21.73 Cr | -14.76 Cr | -34.09 Cr |
| Diluted EPS | - | -7.71 | -4.34 | -2.95 | -6.80 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 163.85 Cr | 150.87 Cr | 101.53 Cr | 66.27 Cr |
| Current Assets | - | 39.22 Cr | 37.89 Cr | 32.51 Cr | 10.44 Cr |
| Cash & Equivalents | - | 79.95 L | 59.58 L | 26.31 L | 28.78 L |
| Inventory | - | 13.90 Cr | 19.04 Cr | 24.50 Cr | 1.82 Cr |
| Receivables | - | 2.48 Cr | 3.59 Cr | 1.49 Cr | 4.12 L |
| Total Liabilities | - | 45.57 Cr | 54.19 Cr | 17.82 Cr | 16.65 Cr |
| Current Liabilities | - | 42.73 Cr | 48.87 Cr | 17.15 Cr | 16.77 Cr |
| Long Term Debt | - | 0 | 0 | 0 | 0 |
| Total Debt | - | 21.77 Cr | 22.08 Cr | 2.13 Cr | 9.75 Cr |
| Total Equity | - | 118.29 Cr | 96.68 Cr | 83.71 Cr | 49.62 Cr |
| Shares Outstanding | - | 5.01 Cr | 5.01 Cr | 5.01 Cr | 5.01 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -17.30 Cr | 1.83 Cr | -2.88 Cr | -7.37 L |
| Investing Cash Flow | - | 11.19 Cr | -39.79 L | 8.21 Cr | 33.91 L |
| Financing Cash Flow | - | -4.16 Cr | -1.63 Cr | -5.66 Cr | -25.29 L |
| Capital Expenditure | - | - | -1.66 Cr | - | - |
| Free Cash Flow | - | -17.30 Cr | 17.08 L | -2.88 Cr | -7.37 L |
| Net Change in Cash | - | -10.27 Cr | -19.10 L | -33.33 L | 1.25 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 17.8% | 27.9% | 25.5% | 5.2% |
| Operating Margin % | - | -14.0% | -8.2% | -4.2% | -53.2% |
| Net Margin % | - | -29.8% | -20.8% | -10.4% | -135.6% |
| ROE % | - | -32.7% | -22.5% | -17.6% | -68.7% |
| ROCE % | - | -14.9% | -8.3% | -7.2% | -27.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LASA
Lasa Supergenerics Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPbXNzVXlFQ1FOZzY2Q2ZwQnVfbEhyRGFOUmk0SHhEQ3FxMkJyV19ueDUwdWhkQlFpZGoyd2MtYUJlaGY0XzdIOGpWVkVUdTkwWHdtOG5XUVdvbldjWE5JYkR0cU9xRTExMEEyM1BoMEw2X3dZTGMyM3oza19KQ2tOMm93YXNKMENPZFhRUw…
Lasa Supergenerics accepts Ganesh Potdar resignation as WTD - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOX0oxT3hTdjdENXU3aXRjM2Z0bGdGMnVPWmtYQTF1cVV0NXJlSnpxcC1ZbjY3alQzaUF4Vkc4YjVsazRnazFqYTRXcjVWSENwVnpkRGtSZ2owNkJ1eVBkYy1OODVnLS1CUUhUR2xiOTdEcF9POUJnbkpQX2JYUW9IUVVFU0pSdlo3dFJ0X0…
Lasa (LASA.NS) Latest: Posts a 1.57% Gain to ₹7.10 on the Day; Next Test: the Supplied Trading Band Runs From ₹6.74 to ₹7.46 in the Available Record - Median Line - siam.in
<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxON21FbGFqR0x4MHR6ZEktb3pGT2EtMXk4bGFoeEtaN0NoMFdRakxHQmd0QTlQQ2FvbEUxTTZzM0ZvNkRLQzhkS1JQSmJPajlQSFpjTXhFZGNVQjV1WFpFbmNMNE5oRDRmZ25rbXhaYU1KRlVfckhpMjRDTkEwcVlmUHA5NXY2NUd6dWcxcW…
LASA Supergenerics Q2 2026 Earnings: Revenue Plunges 82% YoY; EPS Turns Negative at ₹-6.8 - Earnings Miss Streak - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbnBnWlVPS3R6NzVTeWxSOHVMX0lXX1ZYWXZrejJxeFY2aDNpcF9iX20tREFuZWdoQ2dMVkZmRmF6MmpMU0FBLVgzZmZWSDY3dlJBdHNreXpfcGFKT2M4Z09fa2gyUldaU1NDVERibGthaExGbDVBTkhOTm9DZTlqUllDeTQ5Mnh3YUFNQ3…
Lasa Supergenerics Share Price Target 2026: Rs 8.56 Analyst Forecast - Univest
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9jMllsVC1POTI1TnBVM1RNY19lczMxUEVPZEZaYk1meFRDMlZ6bG8ybDRSLVZJX0FiaTZhb2pGUGhFLUk2NEJubE4xcmpBUlhPUWVpRFlCU2ZmOWJFSUZ2dXRvUFhqaUFJVUgtR3JCM19nWDlpWmc?oc=5" target="_blank">Lasa Sup…
Lasa Supergenerics Ltd. Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNWW4zSVhJTnBSXzR4NThHdFRGZXh6Um5WODl6WFlUbThTUTh0SThLUGhlRUROS2kxbzliV1M5RnVfdndYbVUzR184MHhnY0tMZkhfV0VVQWJ3RDB4QmJCOFNvbmZSRW9nT0NUXzJyb1pzUnpCMFFLZzFwZ2lMM0l2eFRQZmJKUmNSd3NoeU…
LASA — Frequently Asked Questions
What is the current share price of Lasa Supergenerics Limited (LASA)?
As of 2026-09-20 09:43 IST, Lasa Supergenerics Limited (LASA) trades at ₹6.73 on NSE. Its 52-week range is ₹5.67 to ₹13.92.
What is the market capitalisation of LASA?
Lasa Supergenerics Limited (LASA) has a market capitalisation of ₹33.72 Cr on NSE.
What is the P/E ratio of LASA?
LASA trades at a trailing price-to-earnings (P/E) ratio of -2.05. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 0.66.
What is the return on equity (ROE) of LASA?
LASA has a return on equity (ROE) of -68.70%. Its return on capital employed (ROCE) is -69.14%.
Is LASA a good stock to buy?
This page provides a data-driven analysis of Lasa Supergenerics Limited (LASA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.